---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-23-000411"
form_type: "8-K"
ticker: "LAB"
cik: "0001162194"
company_name: "STANDARD BIOTOOLS INC."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T13:13:08.219973+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Standard BioTools Q4 rev $27M (+8.3% seq); FY22 rev $97.9M vs $130.6M; guides 2023 flat-to-mod growth

## Summary
- Q4 2022 GAAP revenue $27.0M; core product/service rev $26.8M, up 8.3% sequentially.
- Full year GAAP revenue $97.9M (down from $130.6M in 2021); core rev $94.5M vs $111.6M.
- Q4 product margin GAAP 40.9% (+620 bps seq), non-GAAP 52.9% (+520 bps); opex down 16% seq to $32.3M.
- 2023 guidance: flat-to-moderate core rev growth; GAAP opex ~$118-123M (20% reduction); Q4 GAAP gross margin 52-55%.
- Cash $165.8M at year-end; expects positive free cash flow by end of 2024; restructuring to cut >$30M opex annually.

## SEC filing metadata
- accession: 0000950142-23-000411
- form_type: 8-K
- ticker: LAB
- cik: 0001162194
- company_name: STANDARD BIOTOOLS INC.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/eh230318897_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-23-000411
- JSON: https://secwatch.observer/filing/0000950142-23-000411.json
- Plain text: https://secwatch.observer/filing/0000950142-23-000411.txt

## Key facts
- Earnings Releases
  STANDARD BIOTOOLS INC. reported the fiscal year ended December 31, 2022 results: revenue $97.9 million. Guidance reaffirmed.
  - Period: the fiscal year ended December 31, 2022
  - Revenue: $97.9 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: GAAP revenues were $97.9 million compared to $130.6 million in 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm
- Earnings Releases
  STANDARD BIOTOOLS INC. updated its 2023 guidance (initiated).
  - Period: 2023
  - Guidance: initiated
  - Result: guidance update
  source text: For 2023, Standard BioTools expects flat-to-moderate growth in core product and service revenues relative to 2022 core product and service revenues of $94.5 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm
- Earnings Releases
  STANDARD BIOTOOLS INC. reported the three months ended December 31, 2022 results: revenue $27.0 million. Guidance reaffirmed.
  - Period: the three months ended December 31, 2022
  - Revenue: $27.0 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Fourth quarter 2022 GAAP revenues were $27.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1162194/000095014223000411/0000950142-23-000411-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.